Recent News

Kaligia Biosciences receives EU approval for its RBA-2 device for rapid COVID-19 screening

Kaligia Biosciences’ Rapid Biofluid Analyzer 2 has received a CE mark and is ready for the European market.

We are awaiting approval by the FDA in US and by DHSC in UK.

Kaligia Biosciences

On the forefront of healthcare technology

Revolutionary non-invasive point of care devices.

Our Basic Process

Quantifiable Results, Unprecedented Speed.

Kaligia Biosciences is tapping into the power of emerging technologies and creative problem solving to innovate a new breed of sensing devices. These devices, which produce quantifiable results with unprecedented speed and accuracy, align with Kaligia Bieosciences’s mission to redefine medical diagnosis and transform healthcare delivery from reactive to proactive.


Sample fluid collected from patient.


High-intensity laser and detector records unique light signatures.

Machine Learning

Proprietary algorithms analyze the light signatures.

Rapid Results

Results delivered almost instantaneously.
Kaligia Biosciences

Our Products

Non-Invasive COVID-19 Tests

Learn More

Non-Invasive Glucose Skin Test

Learn More

Minimally-Invasive Rapid Blood Test

Learn More
Medical Partnerships

Solving Complex Problems Together

Kaligia Bioscience has begun clinical trials in partnership with numerous hospitals in the Tampa Bay area.

News and Media

Our Latest Posts


Company News

Tampa Bay Company Develops Coronavirus Saliva Test

September 28, 2020
LARGO, Fla. — A Tampa Bay company is awaiting FDA approval for a COVID-19 testing…
Product Information

Kaligia Bioscience’s COVID-19 Rapid Biofluid Analyzer 2 Featured on ABC Action News

June 10, 2020
The co-founder and CEO of Kaligia Bioscience, Fazal Fazlin, spoke with ABC News regarding the partnership…
Research & Partnerships

Kaligia Bioscience COVID-19 Clinical Trials Begin – Tampa Bay Times

May 22, 2020
Kaligia Bioscience has begun clinical tests with it’s Rapid Biofluid Analyzer utilizing saliva to detect COVID-19 in…